Publication:
Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients

dc.contributor.authorPanjaporn Chaichanaen_US
dc.contributor.authorTamaki Okabayashien_US
dc.contributor.authorOrapim Puipromen_US
dc.contributor.authorMikiko Sasayamaen_US
dc.contributor.authorTadahiro Sasakien_US
dc.contributor.authorAkifumi Yamashitaen_US
dc.contributor.authorPongrama Ramasootaen_US
dc.contributor.authorTakeshi Kurosuen_US
dc.contributor.authorKazuyoshi Ikutaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherOsaka Universityen_US
dc.contributor.otherJapan International Cooperation Agencyen_US
dc.date.accessioned2018-11-09T01:45:08Z
dc.date.available2018-11-09T01:45:08Z
dc.date.issued2014-03-18en_US
dc.description.abstractBackground: The majority of dengue patients infected with any serotype of dengue virus (DENV) are asymptomatic, but the remainder may develop a wide spectrum of clinical symptoms, ranging from mild dengue fever (DF) to severe dengue hemorrhagic fever (DHF). Severe cases occur more often in patients who experience a secondary infection with a different virus serotype. A phenomenon called antibody-dependent enhancement (ADE) has been proposed to explain the onset of these severe cases, but the exact mechanism of ADE remains unclear. Methodology/Principal Finding: Virus neutralization and ADE assays were performed using ultracentrifugation supernatants of acute-phase sera from patients with secondary infections or human monoclonal antibodies (HuMAbs) as anti-DENV antibodies. Virus sources included infectious serum-derived viruses from the ultracentrifugation precipitates, laboratory-culture adapted DENV, or recombinant DENVs derived from patient sera. In contrast to the high levels of ADE observed with laboratory virus strains, low ADE was observed with autologous patient-derived viruses, when patient sera were used to provide the antibody component in the ADE assays. Similar results were obtained using samples from DF and DHF patients. Recombinant-viruses derived from DHF patients showed only minor differences in neutralization and ADE activity in the presence of HuMAbs or plasma derived from the same DHF patient. Conclusion/Significance: Serum or plasma taken from patients during the acute phase of a secondary infection showed high levels of ADE, but no neutralization activity, when assayed in the presence of laboratory-adapted virus strains. By contrast, serum or plasma from the same patient showed high levels of neutralization activity but failed to induce significant ADE when the assays were performed with autologous virus. These results demonstrate the significance of the virus source when measuring ADE. They also suggest that repeated passage of DENV in cell culture has endowed it with the capacity to induce high levels of ADE. © 2014 Chaichana et al.en_US
dc.identifier.citationPLoS ONE. Vol.9, No.3 (2014)en_US
dc.identifier.doi10.1371/journal.pone.0092173en_US
dc.identifier.issn19326203en_US
dc.identifier.other2-s2.0-84898658030en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/33035
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84898658030&origin=inwarden_US
dc.subjectAgricultural and Biological Sciencesen_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleLow levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84898658030&origin=inwarden_US

Files

Collections